I
nfantile hemangioma, the most common tumor of infancy, affects 10 percent of infants, with a female-to-male ratio of 3:1 and a preponderance in premature infants and Cauasians. [1] [2] [3] [4] Infantile hemangioma is characterized by rapid growth during infancy (proliferating phase), typified by excessive angiogenesis. This is inevitably followed by spontaneous involution over 1 to 5 years (involuting phase) when the cellular elements are gradually replaced by fibrofatty deposition with continued improvement up to the age of 12 years (involuted phase). [1] [2] [3] 5 Proliferating infantile hemangioma is composed of a heterogeneous population of cells of different lineages, predominantly immature endothelial cells, 2, 3 and a lesser abundance of cells of the myeloid 6, 7 and mesenchymal lineages. 8, 9 There is increasing evidence that infantile hemangioma is a disorder of aberrant proliferation and differentiation of primitive mesoderm-derived neural crest phenotypic cells. 10 This primitive phenotype that gives rise to a he-mogenic endothelium intermediate 11 with the ability to undergo primitive erythropoiesis 12 and terminal mesenchymal differentiation 9 is potentially governed by the renin-angiotensin system. 13 The identification of this primitive population within proliferating infantile hemangioma infers a possible embryonic stem cell origin for infantile hemangioma. 10, 14 This article reviews current pharmacologic therapies for problematic proliferating infantile hemangioma. We present the increasing evidence of various cell surface receptors and cytokines governing embryonic stem cell-derived primitive mesoderm differentiation pathways. Our data provide some insights into the mechanism of action of current therapeutic agents that explain and rationalize their observed clinical responses.
GLUCOCORTICOID THERAPY
Glucocorticoids were serendipitously discovered to induce accelerated regression of proliferating infantile hemangioma in the 1960s 15, 16 and have remained the mainstay treatment for problematic proliferating infantile hemangioma for over 40 years. 17 There are two forms of glucocorticoid therapy. High-dose systemic oral prednisone (or an equivalent dose of prednisolone) is administered typically at 2 to 3 mg/kg/day, usually as a single dose 17, 18 over an average duration of 2 months, 19 followed by a rapid taper over 2 months. 17 Intralesional corticosteroid administration is preferred for localized nonperiorbital lesions. Intralesional triamcinolone acetonide is usually administered singly, 18 although it has been used in combination with dexamethasone sodium phosphate for high-risk lesions. 18 Injections usually consist of 20 mg of triamcinolone acetonide and 3 mg of betamethasone in 1 ml total volume, 20 although there have been other reports of this dose being doubled. 21 A weight-based protocol of up to 3 to 5 mg/kg per injection has also been used. 22 The injection may be repeated at 6-week intervals and usually one to three injections are required. 23 This heterogeneity in dosing probably reflects the size of the lesion(s) being treated.
Over the past four decades, several studies have reported variable effectiveness of steroid therapy on infantile hemangioma, with a dramatic response occurring in 30 to 53 percent of cases, equivocal results occurring in 35 to 40 percent cases, and ongoing progression occurring in the remainder. 17, 19, 24 A meta-analysis shows a 14 to 37 percent rate of rebound growth during dose tapering, 19 often requiring reinstitution of steroids. Despite the wide variations in the dosages used and different selection criteria, an overall good response rate of 35 to 90 percent to intralesional steroid therapy has been reported. 23 The side effects of systemic glucocorticoid therapy are well documented 17, 22 and are relatively common, even for short treatment periods. These include cushingoid facies, weight gain, hypertension, cataracts, glucose intolerance, and adrenal suppression. Growth retardation is more common if treatment is started before 3 months of age or continued for 6 months or longer, presumably because of decreased somatomedin and therefore collagen synthesis. However, accelerated catchup growth occurs, reassuming pretreatment growth, following cessation of systemic steroid therapy. 17, 22 There is also increasing evidence of reduced brain growth with steroid use in premature infants. 25 Intralesional steroid therapy is associated with fewer systemic side effects compared with systemic administration. 20 -22 However, reports of central retinal artery occlusion following steroid injection of periorbital infantile hemangiomas has been reported. 26 The demonstration of mesenchymal stem cells in infantile hemangioma 8 and the presumed mesenchymal/mesodermal 27 origin of infantile hemangioma has led to the assumption that these cells through differentiation form a crucial role in the formation of the fibrofatty residuum, typically seen in involuted lesions. The recent discovery of a neural crest phenotypic precursor in proliferating infantile hemangioma that coexpresses mesenchyme-associated cell proteins 10 has led us to propose that these neural crest phenotypic cells have a mesenchymal and thus adipocytic differentiation capacity, corroborating previous reports. 28, 29 Glucocorticoids have been implicated in the acceleration, but not the initiation, of adipocytic differentiation. 30 The effect of glucocorticoids on promoting apoptosis by means of up-regulation of the mitochondrial cytochrome b gene 31 but not the clusterin gene 32 has been proposed as a possible mechanism of action of glucocorticoid therapy. Recent evidence also suggests that glucocorticoids induce adipocytic differentiation through inhibition of preadipocyte factor-1, an inhibitor of adipogenesis. 33 We have recently demonstrated expression of preadipocyte factor-1 in the endothelium of proliferating infantile hemangioma capillaries that is lost as the lesion involutes, 9 suggesting a possible mechanism for a critical role in the interplay of glucocorticoids and preadipocyte factor-1 in steroid-induced involution of infantile hemangioma.
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Another possible action of glucocorticoids involves its effect on peroxisome proliferator-activated receptor-␥, a transcription factor regulating adipocyte differentiation from preadipocytes. 34 Glucocorticoids have been shown to induce peroxisome proliferator-activated receptor-␥ gene expression during conversion of mesenchymal stem cells into adipocytes. 35 Considered together, we speculate that glucocorticoids exert a dual effect by negating the antiadipocytic differentiation effect of preadipocyte factor-1 and promoting adipogenesis through increasing the expression of peroxisome proliferator-activated receptor-␥. Recent evidence has shown a critical role for angiotensin II, not only in proliferation of infantile hemangioma capillaries but also in the maintenance of vascular endothelial growth factor (VEGF) secretion by mesenchymal stem cells and preventing terminal adipocytic differentiation during the proliferation phase of infantile hemangioma. 13 These observations have been supported by recent data from Greenberger et al. 36 demonstrating a role for corticosteroids in suppressing VEGF-A secretion in infantile hemangioma-derived stem cells. 36 These authors suggest a direct inhibitory effect of dexamethasone on vasculogenesis. The relative effects of steroids on adipogenesis and vasculogenesis remain a topic for further investigation. We propose that these mechanisms account for the variable clinical response of infantile hemangioma to glucocorticoid therapy with respect to the stage of differentiation of infantile hemangioma and the time point at which treatment is initiated.
INTERFERON THERAPY
During investigation into the antiviral agent interferon ␣-2a for the treatment of human immunodeficiency virus, it was noted that there was improvement of the patients' Kaposi sarcomas. [37] [38] [39] Anecdotal reports on the response of infantile hemangioma to interferon 40, 41 and subsequent clinical trials 42, 43 have led to its use as a second-line treatment for steroidresistant infantile hemangiomas. 44 Two forms of interferon therapy are used for problematic proliferating infantile hemangioma, namely, interferon ␣-2a and interferon ␣-2b. Interferon ␣-2a is administered as daily subcutaneous injections at a starting dose of 1 million IU/m 2 body surface area, increasing to 3 million IU/m 2 during the first month of treatment, for a period of 2 to 12 months. 41, 45, 46 The response rate to interferon is 90 percent in steroid-resistant infantile hemangiomas. However, the response is less dramatic and takes longer than steroid therapy. 44 Premature withdrawal of interferon is associated with rebound growth, necessitating reintroduction of the treatment. Side effects of interferon therapy include fever, flu-like symptoms, rash, gastrointestinal symptoms, transient neutropenia, and elevated liver enzymes. 44, 46, 47 The most serious complication of interferon therapy is neurotoxicity affecting mainly higher cortical function and, to a lesser extent, motor function. 44 There have also been reports of peripheral neuropathy. 44 These side effects are usually reversible following cessation of therapy. The most serious neurotoxic side effect of interferon is spastic diplegia, which affects up to 20 percent of patients. 48 Of concern are reported cases of persistent spastic diplegia 49 despite cessation of interferon ␣-2a. The underlying mechanism of interferon toxicity is unknown but appears to be related to the duration of treatment and not the maximal daily dosage, as they appear late during treatment. Regular monitoring with neurologic assessment, full blood count, and liver function testing should be performed during treatment.
The successful use of topical imiquimod 50, 51 in treating proliferating infantile hemangioma, has been attributed to its ability to induce interferon ␣ production, 50, 51 suggesting a common final pathway in the observed effect of interferon and imiquimod therapy.
Interferon-induced genes have been shown to be up-regulated during the involuting phase of infantile hemangioma. 52 Thus, the induction of these genes provides the basis of interferon therapy. Interferon ␣-2a inhibits the locomotion of endothelial cells in vitro, inhibits fibroblast growth factor-2, and has been shown to inhibit angiogenesis. 53, 54 It has also been shown that the epidermis overlying proliferating infantile hemangioma expresses less interferon ␤ than the normal epidermis. 55 This may indicate a role for paracrine effects of nonendothelial cells in the pathogenesis of infantile hemangioma. Further work with in vitro human models 56 may allow the study of its precise mechanism of action.
Although interferon ␣-2a is effective in treating massive or life-threatening steroid-resistant infantile hemangiomas, its potential serious side effects have limited its use, and vincristine has emerged as an alternative second-line therapy. Because of its toxicities and the emergence of more effective therapeutic options, interferon should be used as a last-resort therapy for problematic infantile hemangiomas.
VINCRISTINE THERAPY
Vincristine belongs to the vinca alkaloids class of drugs, which act predominantly as inhibitors of mitosis. 57 The use of vincristine for adult and pediatric malignancies is well documented. Its application in infantile hemangioma, although limited, has been documented in life-threatening steroid-and/or interferon-resistant infantile hemangiomas. 58, 59 The dosage of vincristine for infantile hemangioma is 0.05 mg/m 2 in infants weighing less than 10 kg, and 0.75 to 1.5 mg/m 2 for infants weighing more than 10 kg, given intravenously through a central venous line once weekly for three to four doses, 45,58 -61 with dosing intervals varying 1 to 3 weeks.
Side effects of vincristine include neurotoxicity, with irritability, loss of deep tendon reflexes, constipation, abdominal pain, paralytic ileus, cranial nerve palsies, and bone pain (commonly of the jaw) reported. 61 Neurotoxicity is usually not as marked in children or infants, as observed in adults. Other side effects include alopecia, rash and, uncommonly, myelosuppression. 61 Vincristine is a vesicant, and the risk of extravasation necessitates administration through a central venous line or cautious administration through a peripheral line. Supervision by a pediatric oncologist with regular neurologic examination with full blood count during treatment is essential. 60 Vincristine inhibits angiogenesis by preventing cell proliferation through inhibition of cell mitosis. 57 This occurs at metaphase by preventing tubulin polymerization and thus not allowing microtubule formation, and the induction of microtubule depolymerization leading to Bcl-2 phosphorylation, resulting in loss of its ability to form heterodimers with Bax leading to eventual induction of cellular apoptosis. 62, 63 It is interesting that during involution of infantile hemangioma the levels of Bcl-2 start to decrease, with a concomitant increase in Bax levels, allowing for an increase in Bax homodimerization with subsequent cellular apoptosis. 64 Experimental models have shown favorable results with lower dosing of vincristine when given concomitantly with an angiogenic inhibitor, suggesting a critical role of vincristine in inducing terminal apoptotic pathways in compromised cells. 65 
␤-BLOCKER THERAPY
The recent serendipitous discovery of accelerated involution of infantile hemangioma induced by propranolol, 66 a nonselective ␤-blocker;
and acebutalol, 67 a predominantly ␤ 1 -adrenoreceptor blocker, 68 has resulted in a significant paradigm shift in the treatment of problematic proliferating infantile hemangioma. Propranolol is now the preferred treatment for problematic proliferating infantile hemangioma. 69 -75 The mechanism of action of ␤-blockers on proliferating infantile hemangioma is unknown, although their effects on ␤-adrenergic receptor stimulation, 68 down-regulation of angiogenic growth factors, 66, 76, 77 reduction in expression of matrix metalloprotinases, 77 and induction of apoptosis 78 have been suggested. Most reports on propranolol therapy use a 2-to 3-mg/kg/day dosing regimen given in two to three divided doses, 69 -71,79 with treatment courses ranging from 6 weeks 6 to 7 months, 71 usually with a 24-hour hospital stay during initiation of therapy and regular hemodynamic monitoring during the first 6 hours of treatment. 70 We have recently shown that low-dose propranolol at 1.5 mg/kg/ day is sufficient to induce accelerated involution of infantile hemangioma in the majority of patients (Fig. 1) , with a small subgroup, all female patients, requiring a dosage of 2 mg/kg/day. 73, 80 The dosage of acebutolol in the treatment of infantile hemangioma is 8 to 10 mg/kg/day, with clinical responses observed 1 month after initiation of treatment. 67, 81 The optimal duration of treatment remains to be determined. Topical ␤-blockers such as timolol, a nonselective ␤-blocker, administered either by two drops of 0.5% timolol maleate ophthalmic solution 82 or as a gel preparation applied twice daily directly onto the infantile hemangioma, 83 have shown promising results. Although ␤-blockers have a long and good safety record in the treatment of young children with hypertension and other cardiovascular diseases, 84 this may not be simply extrapolated to infants (some of whom are born prematurely) and young children with infantile hemangioma, who are otherwise normotensive. 80 The potential adverse effects of propranolol include bradycardia, hypotension, and hypoglycemia, 85 with recent reports highlighting symptomatic and potentially fatal hypoglycemia in this patient cohort. 86, 87 Caution has justifiably been raised regarding the casual use of this group of drugs for this novel indication in an otherwise normotensive population. 80, 85 The need for large multicenter trials, such as the one currently in progress, 85 will possibly define the clinical indications and appropriate treatment protocols for this condition.
The identification of angiotensin-converting enzyme as a cell surface protein associated with the Plastic and Reconstructive Surgery • August 2011 hemangioblast 88 has led us to discover the expression of this protein on the immature capillaries of proliferating infantile hemangioma. 13 We have also demonstrated the expression of the angiotensin receptor 2 on these same capillaries. 13 The presence of both angiotensin-converting enzyme and angiotensin receptor 2 within proliferating infantile hemangioma suggests that the local angiotensin II produced by the conversion of angiotensin I by angiotensin-converting enzyme acts in an autocrine/paracrine fashion. This coupled with the observation of increased renin levels in premature, 89 female, 90 and Caucasian infants 91 corresponding to a higher incidence of infantile hemangioma in these groups of patients 2 has led us to investigate the role of the renin-angiotensin system in infantile hemangioma. 13 Angiotensin II causes secretion of VEGF from mesenchymal stem cells, 92 which are present within infantile hemangioma, 8 and proliferation of CD34 ϩ cells. 93 Angiotensin II has also been reported to prevent terminal differentiation of mesenchymal stem cells. 94 Considered together, it is exciting to speculate that angiotensin II drives proliferation of the immature endothelial cells, which express CD34, 95 within proliferating infan- Volume 128, Number 2 • Pharmacotherapy for Infantile Hemangioma tile hemangioma, and maintain continual VEGF production from the mesenchymal stem cells within the lesion, 8 preventing terminal adipocytic differentiation, although this remains to be determined conclusively. The effect of angiotensin II on angiotensin receptor 2 has been demonstrated to cause an increase in Pax-2 expression in mouse embryonal mesenchymal epithelial cells. 96 Pax-2 is a homeobox 2 gene associated with progenitor cells derived from embryonic stem cells 97 and in mesenchymal condensates involved in early renal organogenesis, 98 which is lost as progenitor cells differentiate. 97, 98 The demonstration of Wnt activation by Pax-2, coupled with the knowledge of prevention of terminal adipocytic differentiation by Wnt, 99 may reveal novel pathways in adipogenic ontogeny in infantile hemangioma. The implication of a VEGF-notch signaling pathway in proliferating infantile hemangioma has also been demonstrated, 100 and the effect of notch signaling on progenitor cell proliferation is reliant on normal Wnt signaling. 101 Interestingly, Wnt signaling is involved not only in blocking apoptosis but also in preventing terminal differentiation of preadipocytes. 99 The identification of osteoprotegerin, a secreted glycoprotein, belonging to the tumor necrosis factor receptor superfamily 102 within proliferating infantile hemangioma 103,104 also reveals a novel antiapoptotic pathway in infantile hemangioma. Osteoprotegerin acts to stimulate cell survival through its action as a receptor for tumor necrosis factor-related apoptosis ligand, by binding to tumor necrosis factor-related apoptosis ligand and preventing its interaction with functional death receptors, therefore preventing apoptosis. 102 Angiotensin II has also been previously reported to stimulate osteoprotegerin production. 105 It is known that ␤-blockers, such as propranolol, partly reduce renin activity in the periphery by reducing plasma renin activity. 106 Low renin activity in turn reduces angiotensin I and eventually angiotensin II levels. Considered together, we infer that a reduction in angiotensin II levels causes a reduction in proliferation of the hemogenic endothelium of proliferating infantile hemangioma together with an increased rate of cellular apoptosis through the tumor necrosis factor-related apoptosis ligand pathway. A reduction in renin levels that physiologically occurs after the first year of life 107 and the inferred mechanism of action of propranolol through the renin-angiotensin system is thus able to account for both the effect of ␤-blockers on infantile hemangioma and the natural progression of infantile hemangioma. It is intriguing that although the high systemic levels of renin during infancy may account for the rapid proliferation of infantile hemangioma, there is also the possibility of a local renin-angiotensin system including local secretion of renin as observed in the vasculature and adipose tissue 108 and from mast cells, 109 which may contribute to the available angiotensin II to the tumor, which may explain the observed response of infantile hemangiomas to topical application of timolol. 82, 83 However, this remains a topic of further investigation.
THE FUTURE
The recent discovery of the crucial role of stem cells 10 and the inferred role of the renin-angiotensin system 13 in the biology of infantile hemangioma underscores the possibility of using even more targeted therapy on this enigmatic condition. Our preliminary clinical trial using an angiotensin-converting enzyme inhibitor has shown promising results, 80 although this is a subject for a separate report. This has raised the possibility for the novel use of inhibitors of angiotensin-converting enzyme and angiotensin receptor as modulators of the renin-angiotensin system in the treatment of infantile hemangioma. The novel vasopeptidase inhibitors that simultaneously inhibit neutral endopeptidase and serum angiotensin-converting enzyme activity 110 may also offer potential reninangiotensin system modulation. Further study will be needed to verify the potential role of these modulators of the renin-angiotensin system in the treatment of infantile hemangioma. The discovery of the potential role of these traditional antihypertensive agents in stem cell biology may lead to better understanding of developmental biology and tumor stem cell growth. 
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